Article Menu

Export Article

More by Authors Links

Article Data

  • Views 2785
  • Dowloads 156

Commentaries

Open Access

SARS-CoV-2 vaccination in gynecologic oncology

  • Zachary Alholm1,*,
  • Daniel Spinosa2
  • Rebecca A. Previs3
  • Stephanie L. Shuey4
  • David M. O’Malley5
  • Leslie Randall6
  • Brian Slomovitz7
  • Bradley J. Monk8

1Department of Obstetrics and Gynecology, University of Arizona-Phoenix, Phoenix, AZ 85004, USA

2Department of Obstetrics and Gynecology, Duke University Health System, Durham, NC 27710, USA

3Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Duke Cancer Institute, Duke University Medical Center, Durham, NC 27710, USA

4Department of Pharmacy, Duke University Medical Center, Durham, NC 27710, USA

5Division of Gynecology Oncology, The Ohio State University and the James Comprehensive Cancer Center, Columbus, OH 43210, USA

6Division of Gynecologic Oncology, Massey Cancer Center, Virginia Commonwealth University, Richmond, VA 23284, USA

7Division of Gynecology Oncology, Broward Health, Florida International University, Fort Lauderdale, FL 33199, USA

8Arizona Oncology (US Oncology Network), University of Arizona, Creighton University, Phoenix, AZ 85721, USA

DOI: 10.31083/j.ejgo.2021.02.2491 Vol.42,Issue 2,April 2021 pp.402-404

Submitted: 13 April 2021 Accepted: 15 April 2021

Published: 15 April 2021

*Corresponding Author(s): Zachary Alholm E-mail: zalholm@gmail.com

PDF (160.5 kB) View Full-text

Cite and Share

Zachary Alholm, Daniel Spinosa,Rebecca A. Previs,Stephanie L. Shuey,David M. O’Malley,Leslie Randall,Brian Slomovitz,Bradley J. Monk. SARS-CoV-2 vaccination in gynecologic oncology. European Journal of Gynaecological Oncology. 2021. 42(2);402-404.

URL:

https://www.ejgo.net/articles/10.31083/j.ejgo.2021.02.2491

References

[1] Dong E, Du H, Gardner L. An interactive web-based dashboard to track COVID-19 in real time. Lancet Infectious Diseases. 2020; 20: 533–534.

[2] Hachem RY, Datoguia T, Siddiqui B, Cruz AF, Mori N, Fakhred- dine S, et al. 372. Comparing the outcome of COVID-19 in cancer and non-cancer patients: an international multicenter study. Open Forum Infectious Diseases. 2020; 7: S256.

[3] United States Food and Drug Administration (FDA) Press Release. FDA Takes Additional Action in Fight Against COVID-19 By Issuing Emergency Use Authorization for Second COVID-19 Vac- cine. 2020. Available at: https://www.fda.gov/news-events/press-announcements/fda-takes-additional-action-fight-against-C OVID-19-issuing-emergency-use-authorization-second-covid (Accessed: 18 January 2021).

[4] Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. New England Journal of Medicine. 2021; 384: 403–416.

[5] Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. New England Journal of Medicine. 2020; 383: 2603–2615.

[6] Centers for Disease Control and Prevention (CDC). Interim clinical considerations for use of mRNA COVID-19 vaccines currently authorized in the United States. 2021. Available at: https://www.cdc.gov/vaccines/COVID-19/info-by-product/clinical-considerations.html (Accessed: 24 Janurary 2021).

[7] Poland GA, Ovsyannikova IG, Kennedy RB. SARS-CoV-2 immunity: review and applications to phase 3 vaccine candidates. Lancet. 2020; 396: 1595–1606.

[8] Widge AT, Rouphael NG, Jackson LA, Anderson EJ, Roberts PC, Makhene M, et al. Durability of responses after SARS-CoV- 2 mRNA-1273 vaccination. New England Journal of Medicine. 2021; 384: 80–82.

[9] Rubin LG, Levin MJ, Ljungman P, Davies EG, Avery R, Tomblyn M, et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clinical Infectious Diseases. 2014; 58: e44–e100.

[10] Johnson & Johnson. Johnson & Johnson COVID-19 Vaccine Authorized by U.S. FDA for Emergency Use—First Single-Shot Vaccine in Fight Against Global Pandemic. 2021. Available at: https://www.jnj.com/johnson-johnson-COVID-19-vaccine-aut horized-by-u-s-fda-for-emergency-usefirst-single-shot-vaccine-in-fight-against-global-pandemic (Accessed: 05 April 2021).

[11] Johnson & Johnson. Johnson & Johnson Statement on COVID-19 Vaccine. 2021. Available at: https://www.jnj.com/johnson-johns on-statement-on-COVID-19-vaccine (Accessed: 13 April 2021).

[12] National Comprehensive Cancer Network. Cancer and COVID-19 Vaccination (Version 1.0.2021). 2021. Available at: https://www.nccn.org/COVID-19/pdf/COVID-19_Vaccinatio n_Guidance_V1.0.pdf (Accessed: 24 January 2021).

Submission Turnaround Time

Top